ReviewAdvances in experimental medicine and biology2026
Data Analysis in Extreme Resolution Mass Spectrometry Untargeted Metabolomics.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mass spectrometry (MS)-based metabolomics is a powerful tool for understanding the complexity of biochemical processes and to identify biomarkers across diverse biological systems. The vast amount of data generated by extreme resolution mass spectrometers poses significant data processing challenges, requiring robust computational approaches and workflows for meaningful data interpretation. This chapter provides a comprehensive overview of current methodologies in MS-based metabolomics data analysis, with a focus on data preprocessing and pretreatment, m/z extraction and annotation, univariate and multivariate statistical approaches, as well as data visualization. We discuss key considerations for ensuring data quality and the growing role of bioinformatics in pathway analysis and metabolite identification. We highlight the transforming role of extreme resolution and mass accuracy enabled by FT-ICR mass spectrometers, and finally, we explore emerging trends, including artificial intelligence-driven insights and real-time data processing, to guide future developments in this rapidly evolving field.
Indexed as
Identifiers
42071148What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.